A New Epoch in Treating Diseases of the Heart
In any medical career, moments stand out when a previous treatment approach is no longer acceptable and a new therapeutic era is ushered in. With the publication of the Diabetes Care and Complications Trial results in 1993,1 intensive diabetes treatment became the standard of care for type 1 diabetes. By showing reductions in both major adverse cardiovascular events (MACE) and total mortality, the 1994 Scandinavian Simvastatin Survival Study (4S)2 initiated a statin arms race, alone and in combination with ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, demonstrating the benefits of progressively lower LDL cholesterol levels on MACE outcomes.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Jonathan Q Purnell, Samuel A Camacho Tags: Editorial Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Type 1 | Endocrinology | Heart | Lipidology | PET Scan | Simvastatin | Statin Therapy | Study | Vytorin | Zetia | Zocor